Evidence map›Paper›PMID 20354814›Full record

ArticleMedical oncology (Northwood, London, England)2011

Anti-cancer effects of 20(S)-protopanoxadiol on human acute lymphoblastic leukemia cell lines Reh and RS4;11.

Lihua Sun, Qiong Wang, Xinmin Liu, Nicolaas H C Brons, Ning Wang, André Steinmetz, Yali Lv, Yonghong Liao, Huyong Zheng

Abstract read
PubMed Publisher
In one paragraph

Article in Medical oncology (Northwood, London, England), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Acute lymphoblastic leukemia of adulthood: progress or not?Current treatment options in oncology · 2011
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

Lihua SunResearch Center for Pharmacology & Toxicology, Institute of Medicinal Plant Development (IMPLAD), Chinese Academy of Medical Sciences and Peking Union Medical College, and Department of Hematology, Beijing Children's Hospital, No. 151, Malianwa North Road, Haidian District, 100193, Beijing, People's Republic of China.
Qiong Wang
Xinmin Liu
Nicolaas H C Brons
Ning Wang
André Steinmetz
Yali Lv
Yonghong Liao
Huyong Zheng
Laboratoire National de Santé · LUPeking Union Medical College Hospital · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNBeijing Children’s Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although the treatment outcome of acute lymphoblastic leukemia (ALL) has been improved in the past decades by combination chemotherapy, toxic side-effects of chemotherapeutics remain a major problem. Therefore, new alternative agents with low toxicity are urgently needed. Natural products provide a rich source of screening potential anti-cancer drugs. 20(S)-protopanoxadiol (PPD), a major gastrointestinal metabolic product of ginsenosides, exhibits promising anti-cancer activity with low toxicity. However, the anti-cancer activity of PPD against ALL has not been evaluated. In this study, we examined the anti-cancer effect of PPD on ALL cell lines Reh and RS4;11. The growth of leukemia cells and normal cells was evaluated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The cell cycle, apoptosis and differentiation was determined by flow cytometry. The results showed that PPD inhibited the growth of Reh and RS4;11 cells, but had little toxicity to peripheral blood mononuclear cells (PBMC). PPD also blocked cell cycle progression from G0/G1 phase and induced cell differentiation. However, cell apoptosis was not affected. These data indicate that PPD exerts anti-cancer effects by stimulating differentiation and inhibiting growth and cell cycle progression of ALL cells.

Indexed as

Antineoplastic AgentsApoptosisCell CycleCell DifferentiationCell Line, TumorCell ProliferationHumansPrecursor Cell Lymphoblastic Leukemia-LymphomaSapogeninsAntineoplastic AgentsprotopanaxadiolSapogenins

Identifiers

PMID20354814
OpenAlexW2074165924

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.